Skip to main
PEN
PEN logo

Penumbra (PEN) Stock Forecast & Price Target

Penumbra (PEN) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 50%
Buy 35%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

Penumbra Inc. achieved significant milestones in December, recording its highest ever volume of Venous Thromboembolism (VTE) procedures, which contributed to an impressive 41% growth as their Flash 2.0 product gained market share in a previously challenging segment. The company's financial performance showed substantial improvement, with a non-GAAP operating margin that increased by 200 basis points year-over-year, supported by enhanced gross margins of 67.4% that surpassed consensus expectations. Additionally, overall Thrombectomy sales reached $222.7 million, reflecting a robust growth of 16.9%, while gross margin improvements were driven by a favorable product mix and enhanced productivity metrics.

Bears say

The analysis of Penumbra Inc.'s outlook reveals concerns regarding a projected decrease in revenue growth to below 12%, driven by limited contributions from new products and slower profitability improvements. Furthermore, revenue estimates for 2025 and 2026 have been reduced from $1.363 billion to $1.349 billion and from $1.545 billion to $1.531 billion, indicating a downward trend in financial performance. Additional risks such as potential competition, operational execution failures, and supply chain disruptions further contribute to the negative sentiment surrounding the stock's future prospects.

Penumbra (PEN) has been analyzed by 20 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 35% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Penumbra and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Penumbra (PEN) Forecast

Analysts have given Penumbra (PEN) a Buy based on their latest research and market trends.

According to 20 analysts, Penumbra (PEN) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $288.95, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $288.95, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Penumbra (PEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.